Production of recombinant coagulation factors: Are humans the best host cells?

Immunogenicity of long-lasting recombinant factor VIII products

(2016) Mathieu Ing et al.   CELLULAR IMMUNOLOGY

The past and future of haemophilia: diagnosis, treatments, and its complications

(2016) Flora Peyvandi et al.   LANCET

A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A

(2016) Flora Peyvandi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor VIII–Mimetic Function of Humanized Bispecific Antibody in Hemophilia A

(2016) Midori Shima et al.   NEW ENGLAND JOURNAL OF MEDICINE

Human cell lines: A promising alternative for recombinant FIX production

(2016) Aline de Sousa Bomfim et al.   PROTEIN EXPRESSION AND PURIFICATION

Transforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)

(2016) Elena Santagostino   THROMBOSIS RESEARCH

Manufacturing process used to produce long-acting recombinant factor VIII Fc fusion protein

(2015) Justin McCue et al.   BIOLOGICALS

Serum-free suspension culturing of human cells: adaptation, growth, and cryopreservation

(2015) Rafael Tagé Biaggio et al.   BIOPROCESS AND BIOSYSTEMS ENGINEERING

The art of CHO cell engineering: A comprehensive retrospect and future perspectives

(2015) Simon Fischer et al.   BIOTECHNOLOGY ADVANCES

Industrial production of clotting factors: Challenges of expression, and choice of host cells

(2015) Sampath R. Kumar   Biotechnology Journal

Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A

(2015) B. A. Konkle et al.   BLOOD

Novel, human cell line-derived recombinant factor VIII (human-cl rhFVIII; Nuwiq®) in adults with severe haemophilia A: efficacy and safety

(2015) T. Lissitchkov et al.   HAEMOPHILIA

Prophylaxis vs. on-demand treatment with Nuwiq®(Human-cl rhFVIII) in adults with severe haemophilia A

(2015) A. Tiede et al.   HAEMOPHILIA

Novel, human cell line-derived recombinant factor VIII (Human-cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokinetics

(2015) A. Klukowska et al.   HAEMOPHILIA

Safety of PEGylated recombinant human full-length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugates

(2015) R. Stidl et al.   HAEMOPHILIA

Industrial production of clotting factors: Challenges of expression, and choice of host cells

(2015) Sampath R. Kumar   Biotechnology Journal

Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A

(2014) T. Calvez et al.   BLOOD

Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011

(2014) P. W. Collins et al.   BLOOD

The choice of mammalian cell host and possibilities for glycosylation engineering

(2014) Michael Butler et al.   CURRENT OPINION IN BIOTECHNOLOGY

Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein

(2014) J. McCue et al.   HAEMOPHILIA

A new recombinant factor VIII: from genetics to clinical use

(2014) Elena Santagostino   Drug Design Development and Therapy

Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B

(2013) Jerry S. Powell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Factor VIII Products and Inhibitor Development in Severe Hemophilia A

(2013) Samantha C. Gouw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Production of Recombinant Therapeutic Proteins in Human Cells: Current Achievements and Future Perspectives

(2013) Virgínia Picanco-Castro et al.   PROTEIN AND PEPTIDE LETTERS

Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

(2012) Darius Ghaderi et al.   Biotechnology & Genetic Engineering Reviews

SK-HEP cells and lentiviral vector for production of human recombinant factor VIII

(2012) Nathalia Gonsales da Rosa et al.   BIOTECHNOLOGY LETTERS

Longer FVIII: the 4th generation

(2012) M. Makris   BLOOD

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients

(2012) J. S. Powell et al.   BLOOD

The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics

(2012) Elisabeth Casademunt et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

(2012) Takehisa Kitazawa et al.   NATURE MEDICINE

Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII

(2012) Helena Sandberg et al.   THROMBOSIS RESEARCH

Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII

(2012) Christoph Kannicht et al.   THROMBOSIS RESEARCH

CHO cells in biotechnology for production of recombinant proteins: current state and further potential

(2011) Jee Yon Kim et al.   APPLIED MICROBIOLOGY AND BIOTECHNOLOGY

Potential impact of the non-human sialic acid N-glycolylneuraminic acid on transplant rejection risk

(2011) Vered Padler-Karavani et al.   XENOTRANSPLANTATION

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

Expression systems for therapeutic glycoprotein production

(2009) Yves Durocher et al.   CURRENT OPINION IN BIOTECHNOLOGY